We have no effective treatment for severe amphetamine dependence. Now, a study from Finland points to an obvious candidate treatment for those meeting DSMIV criteria for intravenous amphetamine dependence. Patients were randomly assigned to Abilify (aripiprazole--15 mg/day), Concerta (methylphenidate controlled release--54 mg/day) or placebo for 20 weeks.

Recently, the FDA approved the Amplichip CYP450 Test (from Roche Diagnostics), which is a device allowing laboratories to quickly find out whether your patient metabolizes drugs too slowly or too quickly.

After reading these articles, you should be able to…

Here are TCPR’s guidelines for how to deal with SSRI non-response.

The following imaginary case vignette helps us examine the clinical relevance of the major findings of the STAR-D trial.

The latest results from the CATIE trial indicate that treatment with Trilafon (perphenazine) is not only much cheaper than treatment with SGAs (second generation antipsychotics), but leads to superior overall quality of life for patients.

Only after thinking long and hard about it, according to the long anticipated results from the CATIE-AD trial. In this study, 421 patients with Alzheimer’s Disease were randomized to double-blind treatment with Zyprexa (mean dose, 3.2 mg/day), Seroquel (34.1 mg/day), Risperdal (0.7 mg/day), or placebo.

Another study has been published on the controversial issue of whether antidepressants increase the risk of suicidality in children.

In the largest ever randomized controlled trial of acupuncture for depression, the treatment did no better than “non-specific” needling; in fact, it did somewhat worse.

It’s been a bad, bad year for Topamax (topiramate). First, the results of four controlled trials of Topamax as monotherapy for mania showed that it outperforms placebo in only two ways: more paresthesia and more weight loss (Kushner et al, Bipolar Disorders 2006;8:15-27).